Cloning And Mutagenesis Market Focusing On The Basis Of Product, Technology, End-User, Region And Forecast 2030: Grand View Research Inc.

San Francisco, 16 Aug 2023: The Report Cloning And Mutagenesis Market Size, Share & Trends Analysis Report By Product (Cloning Kits, Mutagenesis Kits), By Technology (Topo PCR Cloning, Blunt End Cloning), By End-user, By Region, And Segment Forecasts, 2023 – 2030

The global cloning and mutagenesis market size is expected to reach USD 9.44 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 18.97% from 2023 to 2030. Growing focus on protein engineering for drug development and increasing demand for genetically modified products are major factors driving the market. In addition, the rising prevalence of genetic disorders and chronic diseases is increasing the demand for personalized medicine.

Cloning and mutagenesis are the basic methodologies employed in protein engineering during drug development. These techniques help researchers in the modification of protein sequences through insertion, deletion, or substitution of nucleotides to develop therapeutic proteins. In addition, cloning and mutagenesis aid in the development of more efficient and safer drugs, which can be readily available at a lower cost. For instance, currently, there are more than 200 peptide and protein drugs approved by the FDA. Hence, applications of these techniques in protein engineering are likely to fuel market growth over the forecast years.

The COVID-19 pandemic is expected to positively influence market growth. Cloning and mutagenesis techniques are used to clone the SARS-CoV-2 genome. For instance, according to an article published in Nature in May 2020, researchers have constructed a clone of the SARC-CoV-2 genome by using yeast-based method. Modifying or reconstructing genomes is essential for studying methods of infection, replication, and potential drugs and vaccines that might work against the virus. As a result, the usage of these techniques has increased due to COVID-19-related research, which is expected to fuel the market growth during the forecast period.

The growing prevalence of genetic disorders and chronic diseases is increasing the demand for personalized medicine. Cloning and mutagenesis techniques are used in studying a particular disease of an individual to aid diagnosis, develop a treatment plan, and identify the treatment effect. Moreover, increasing funding for personalized medicine is anticipated to boost the applications of cloning and mutagenesis during the study period. For instance, in February 2022, VariantyxS secured funding worth USD 41.5 million to launch novel solutions in precision oncology.

Furthermore, increasing applications of cloning and mutagenesis tools in synthetic biology are accelerating market growth. Synthetic biology is aiding in fine-tuning of already available drugs by using cloning and mutagenesis to improve their therapeutic attributes and produce minimal or no side effects for individuals. Synthetic genes created the way for oncology-focused organizations to develop personalized cancer vaccines to the specific DNA sequence of a patient’s tumor. Several such personalized cancer vaccines are in the clinical phase. There are several gene-based vaccines that are also in development to fight COVID-19, which require cloning and mutagenesis techniques to produce cost-effective and efficient vaccines. Such applications are expected to fuel the market growth during the study period.

On the other hand, high maintenance cost associated with cloning and mutagenesis tools, limited viability of qualified researchers. and the need for advanced training may limit the market growth to a certain extent. However, key players are continuously striving to develop cost-effective instruments and offering several hands-on training programs to overcome the limitations, which is likely to create growth prospects for the market.

Access Research Report of Cloning And Mutagenesis Market @ https://www.grandviewresearch.com/industry-analysis/cloning-mutagenesis-market-report

Cloning And Mutagenesis Market Report Highlights

• By product, the cloning kits segment held the largest share in 2022. This is attributed to the broad range of applications of these kits in biopharmaceuticals, gene therapy, and gene analysis among others
• By technology, the TOPO PCR cloning segment held the largest share in 2022 due to the advantages associated with the technology such as ligation and restriction-free cloning and simple design of primers
• By end-user, the biopharmaceutical and pharmaceutical companies segment held the largest share in 2022 owing to the widespread use of cloning and mutagenesis in biopharmaceuticals for drug discovery and development
• North America dominated the global market in 2022 due to a rise in investment initiatives by the government, increasing incidence of chronic diseases such as cancer, and high demand for biotechnology techniques
• Asia Pacific is expected to grow considerably in the future owing to the increasing R&D investment by governments, rising demand for novel therapeutics, and improving economy

Cloning And Mutagenesis Market Report Scope

Report Attribute	Details
Market size value in 2023	USD 2.80 billion
Revenue forecast in 2030	USD 9.44 billion
Growth rate	CAGR of 18.97% from 2023 to 2030
Base year for estimation	2022
Historical data	2018 – 2021
Forecast period	2023 – 2030

List of Key Players of Cloning And Mutagenesis Market

• Agilent Technologies, Inc.
• Thermo Fisher Scientific, Inc.
• New England Biolabs
• Takara Bio Inc.
• Merck KGaA
• Promega Corporation
• Bio-Rad Laboratories, Inc.
• Danaher
• Jena Bioscience GmbH

Access Press Release of Cloning And Mutagenesis Market @ https://www.grandviewresearch.com/press-release/global-cloning-mutagenesis-market

Biobanks Market Outlook On The Basis Of Product, Service, Biospecimen Type, Biobanks Type, Application, Region And Forecast From 2022 to 2030: Grand View Research Inc.

San Francisco, 1 Nov 2022: The Report Biobanks Market Size, Share & Trends Analysis Report By Product (LIMS, Biobanking Equipment), By Biospecimen Type (Organs, Stem Cells), By Biobank Type (Real, Virtual), By Service, By Application, And Segment Forecasts, 2022 – 2030

The global biobanks market size is expected to reach USD 100.8 billion by 2030, according to a new report by Grand View Research, Inc., registering a CAGR of 4.6% during the forecast period. Biobanks continue to evolve with the introduction of new technologies, such as NGS, and increased focus on genomic medicine. The availability of several types of biospecimens to cater to multiple domains including drug discovery, diagnostics, and others has accelerated the diversification of biorepositories, thereby driving the market. The quality of biospecimens can significantly influence disease testing as well as preclinical and clinical research. Regulatory agencies have played a vital role in spurring the adoption of biobanking services by establishing guidelines for the effective management of samples.

For instance, the U.S. Centers for Disease Control and Prevention (CDC) released guidelines to minimize human hazards while handling COVID-19 samples. This serves as a model for other biorepositories. Furthermore, as the number of research studies and clinical trials related to COVID-19 is increasing, the demand for high-quality biospecimens is expected to significantly increase in the near future, leading to market growth. In addition, population-based cohort studies are facilitated by biorepositories to estimate the actual seroprevalence. Health Catalyst, Inc., through its Touchstone platform, provides national data related to COVID-19 insights. Such factors are anticipated to contribute to the revenue flow in this space.

The ‘BioResource’ was created in October 2021 by RareCan, a Hexham-based healthcare start-up dedicated to improving studies into the uncommon forms of cancer. BioResource will retain samples taken after surgery from cancer patients and make them accessible to researchers across the globe who can use them to cure, prevent, and identify the disease. In December 2021, Newcastle University introduced a new collection of human blood samples and donated human tissue, which could transform efforts to cure rare cancers. The U.K. Biobank has announced that fresh data from a study measuring the range of circulatory metabolomics biomarkers has been added to its database. Nightingale Health, a Finnish business specializing in blood biomarker technologies, conducted the study with 120000 participants.

North America dominated the market with its wide network of centers for biosample storage in the U.S. Moreover, a high number of COVID-19 cases in the U.S. and increased R&D programs have resulted in the establishment of new biorepositories, thereby driving revenue in North America. In Asia Pacific, the market is anticipated to register the fastest growth owing to the ever-expanding pharmaceuticals and clinical research domain across the Asian countries. The key players are engaged in expanding their global reach by partnering with global distributors, mergers, and acquisitions of other players, and entering a strategic alliance with research communities.

Access Research Report of Biobanks Market @ https://www.grandviewresearch.com/industry-analysis/biobanks-industry

Biobanks Market Report Highlights

• The biobanking equipment segment accounted for the maximum revenue share in 2021 owing to the high cost of instruments coupled with an increase in the number of biorepositories
• The biobanking and repository services segment accounted for the largest revenue share in 2021 due to the higher penetration of these services and the increased need for the preservation of biosamples for developing precision medicine and disease-specific research
• Human tissues are the most stored sample for clinical research, resulting in the dominance of this sample type in the market
• The virtual biobanks segment is anticipated to witness the fastest CAGR over the forecast period owing to the growing demand for 3D biospecimens coupled with the need for rare disease data for biomedical research
• The therapeutics application segment accounted for the largest revenue share in 2021 owing to the growing popularity of cell therapies for cancer treatment
• Several pharma/biotech companies have established their private banks to support clinical trials and the development of cell therapies, resulting in revenue growth in this segment

List of Key Players of Biobanks Market

• Thermo Fisher Scientific, Inc.
• Merck KGaA
• QIAGEN
• Hamilton Company
• Avantor
• Tecan Trading AG
• Danaher Corp.
• Becton, Dickinson and Company (BD)
• BioCision
• Taylor-Wharton
• Charles River Laboratories
• Lonza
• STEMCELL Technologies Inc.
• Biovault Family
• PromoCell GmbH
• Precision Cellular Storage Ltd. (Virgin Health Bank)

Access Press Release of Biobanks Market @ https://www.grandviewresearch.com/press-release/global-biobanks-industry 

Biotechnology Reagents & Kits Market Expanding At A CAGR 16.5% For The Forecast Period From 2021 To 2028: Grand View Research Inc.

San Francisco, 2 Aug 2021: The Report Biotechnology Reagents & Kits Market Size, Share & Trends Analysis Report By Kit Type, By Technology, By Tested Parameters, By Micro-Organisms, By Purpose, By End Use, By Region, And Segment Forecasts, 2021 – 2028

The global biotechnology reagents & kits market size is expected to reach USD 1.14 trillion by 2028, registering a CAGR of 16.5% over the forecast period, according to a new report by Grand View Research, Inc. Key factors driving the market include the introduction of novel and advanced products, a rise in investments in the biotechnology sector, and increasing demand for synthetic biology.

Increasing research and development expenditure for life sciences and biotechnology research is expected to drive the market significantly in the coming years. Over the past few decades, the biotechnology sector has witnessed a paradigm shift toward new treatments & drugs, biologically controlled production processes, genetically modified foods, biologically based computing, and new materials, thereby propelling the market growth.

Advancements in molecular diagnostic techniques, such as droplet digital PCR, NGS, and genome-wide sequencing with respect to accuracy, reproducibility, and timeline, have influenced the adoption of biotechnology reagents & kits in the market. The advent of long-read sequencing has made sequencing of longer strands of DNA possible by only reading single DNA molecules, in turn, driving the market growth.

Cell culture technology accounted for the largest revenue share in 2020 owing to the vast product portfolio offered by the key entities and expanding cell biology research. RNA-Seq using NGS technology has emerged as the method of choice for research communities investigating the transcriptome. The virus segment dominated the market in 2020 with increased adoption in cell & gene therapies and vaccinology. The ongoing pandemic has positively impacted the market growth as focused efforts are being conducted for vaccine development using viral vectors.

North America captured the maximum revenue share in 2020 with the U.S. being the largest contributor. The presence of key players coupled with active involvement in research activity has contributed to the maximum share of the region. Asia Pacific is projected to register the fastest CAGR from 2021 to 2028 owing to the improvements in health care infrastructure, entry of large biotechnological organizations, and increasing R&D activities. The key players in the global market are engaged in collaboration with biopharma developers to support their product development process.

Access Research Report of Biotechnology Reagents & Kits Market @ https://www.grandviewresearch.com/industry-analysis/biotechnology-reagent-market

Biotechnology Reagents & Kits Market Report Highlights

• The detection kits segment accounted for the maximum revenue share in 2020 owing to the high demand due to the pandemic
• Amplification kits are anticipated to register a considerable growth rate due to the expanding applications of LAMP technology and PCR
• The development of Point-of-Care (POC) testing has primarily driven the market for on-site testing
• On-site DNA testing administers a broad array of DNA paternity and family relationship, including forensic DNA testing services and prenatal testing options
• Currently, the healthcare segment is the key end-user of the market with the highest penetration of reagents & kits, in terms of usage, in this segment

List of Key Players of Biotechnology Reagents & Kits Market

• Thermo Fisher Scientific
• QIAGEN
• New England Biolabs
• Illumina, Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories
• Hoffmann-La Roche Ltd.
• Merck KGaA
• Promega Corp.
• Takara Bio, Inc.
• LGC Ltd.
• Toyobo Co. Ltd.

Access Press Release of Biotechnology Reagents & Kits Market @ https://www.grandviewresearch.com/press-release/global-biotechnology-reagents-kits-market

Spatial OMICS Market Size Worth $ 484.22 Million By 2028: Grand View Research Inc.

San Francisco, 26 July 2021: The Report Spatial OMICS Market Size, Share & Trends Analysis Report By Technology (Transcriptomics, Genomics, Proteomics), By Product, By Workflow, By Sample Type, By End Use, By Region, And Segment Forecasts, 2021 – 2028

The global spatial OMICS market size is expected to reach USD 484.22 million by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 10.00% from 2021 to 2028. The COVID-19 pandemic slowed down many industries worldwide. However, this market did not face the extensive negative impact of the pandemic.

Startups and well-established players continued their product development and launched novel solutions, democratized their offerings beyond innovators, and engaged in mergers & acquisitions. The spatial OMICS field originated from hyperplexed imaging; however, key players have shifted toward the development of spatial transcriptomics solutions and products.

Rapid advances in the sequencing of tissues, genes, and single cells have resulted in the emergence of spatial genomic sequencing. Spatial OMICS techniques offer quantitative gene expression data and visualization of DNA and RNA mapping within tissue sections. The development of novel technologies for spatial OMICS is anticipated to create lucrative opportunities for the fields of translational research as well as diagnostics.

The spatial genomics technology segment is expected to expand at the fastest CAGR throughout the forecast period owing to a rise in the launch of novel platforms. The integration of high-throughput solutions in transcriptomics, genomics, and proteomics studies has enabled determining the link between disease occurrence and genome position.

The instruments product held the second-largest share in 2020 owing to the launch of new automated solutions for spatial OMIC studies. For instance, in March 2021, Rebus Biosystems launched the new Rebus Esper spatial omics platform for a better understanding of tissue biology. The new integrated and automated instrument delivers quantitative single-cell, single-molecule data with subcellular resolution and spatial context by using advanced fluidics, imaging, chemistry, and bioinformatics solutions.

The fresh frozen sample type is expected to witness significant growth over the forecast period. The advantages of fresh frozen samples in proteomics are validated by several research studies. For instance, in March 2021, a study concluded that Filter Aided Sample Preparation (FASP) technique yielded 20% more protein identifications by using fresh frozen samples than formalin-fixed, paraffin-embedded (FFPE) samples.

North America held the largest share in 2020 owing to an increase in focus on translational research, rise in government support for genomics and sequencing technologies, high demand for personalized medicine, and the presence of a substantial number of translational and academic research organizations.

Access Research Report of Spatial OMICS Market @ https://www.grandviewresearch.com/industry-analysis/spatial-omics-market

Spatial OMICS Market Report Highlights

• By technology, spatial transcriptomics accounted for the largest share in 2020 and is projected to maintain its dominance throughout the forecast period as most of the available products are based on mRNA analysis for positional information
• In terms of product, the consumables segment held the largest revenue share in 2020 owing to the frequent purchase of reagents and probes to run instruments
• Based on workflow, the instrumental analysis segment dominated the market in 2020 owing to the technological advancements and launch of novel products in the market
• The fresh frozen sample type is anticipated to expand at a lucrative CAGR from 2021 to 2028 as fresh frozen tissue preserves the native state of proteins and hence are adopted in spatial proteomics analysis
• On the basis of end use, the academic and translational research institutes dominated the market in 2020 owing to an increase in biomedical research in academic universities

 List of Key Players of Spatial OMICS Market

• 10x Genomics
• Dovetail Genomics
• S2 Genomics, Inc.
• NanoString Technologies, Inc.
• Seven Bridges Genomics
• PerkinElmer, Inc.
• Bio-Techne
• Danaher Corporation
• IonPath, Inc.
• Millennium Science Pty Ltd.
• Akoya Biosciences, Inc.
• Fluidigm Corporation
• Diagenode Diagnostics
• Biognosys AG
• Rebus Biosystems
• Ultivue, Inc.
• Vizgen Corp.
• BioSpyder Technologies
• Bruker
• Brooks Automation, Inc.

Access Press Release of Spatial OMICS Market @ https://www.grandviewresearch.com/press-release/global-spatial-omics-market

Single-use Bioprocessing Market Projected To Expand At A CAGR 16.0%For The Forecast Period From 2021 To 2028: Grand View Research Inc.

San Francisco, 2 June 2021: The Report Single-use Bioprocessing Market Size, Share & Trends Analysis Report By Product (Probes & Sensors, Simple & Peripheral Elements), By Workflow (Downstream, Upstream), By End-use, By Region, And Segment Forecasts, 2021 – 2028

The global single-use bioprocessing market size is expected to reach USD 51.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 16.0% from 2021 to 2028. The adoption rate and demand for single-use equipment have significantly increased in the past few years. This is due to the commercial advantages including cost and time-saving advantages associated with it, thereby driving the market.

The growing adoption of the equipment by in-house as well as contract biomanufacturers has spurred the investment flow in this space. Also, the market is witnessing notable advancements in various product portfolios such as stirring systems, bioreactor designs, disposable probes and sensors, and film technologies, thereby leading to strong revenue growth. Furthermore, the implementation of big data and machine-learning technologies exhibits great potential in advancing single-use-based biomanufacturing processes.

Several manufactures have begun shifting towards automation to ease the process and reduce cost margin. Besides, considering the improved efficiency of disposables in accelerating the biopharmaceuticals production, end-users are undertaking various initiatives to convert their bioprocessing unit into a single-use unit. This is anticipated to create lucrative opportunities for the operating technology and product supplier in the market during the forecast period.

Access Research Report of Single-use Bioprocessing Market @ https://www.grandviewresearch.com/industry-analysis/single-use-bioprocessing-market

Single-use Bioprocessing Market Report Highlights

• The simple and peripheral elements segment accounted for the largest revenue share in 2020 due to diversification of products as well as their frequent usage
• For instance, disposable probes and sensors are witnessing robust growth in terms of adoption within the biopharmaceutical industry, thereby driving the segment
• Furthermore, the introduction of single-use bags integrated with adapters, automation, tubing, ports, connectors, and sensors have attributed to the significant share of this segment
• The apparatus and plants segment is anticipated to grow at a significant pace owing to the expanding applications of products offered in this segment
• The flexibility offered by single-use bioreactor technology is one of the key factors driving investment in the segment
• Furthermore, the presence of a wide array of products for both upstream and downstream processing has resulted in the large revenue share of this segment
• Biopharmaceutical manufacturers are estimated as the largest key end-users of the market
• Facility expansion and increasing adoption of disposables by contract manufacturing organizations is playing a vital role in accelerating the biopharmaceutical manufacturing industry
• North America dominated the market owing to the presence of strong research as well as the commercial base for biopharmaceutical manufacturing
• Moreover, the U.S. is the largest biopharmaceutical market that has positively influenced the adoption of single-use technologies in the region
• The shifting focus of U.S.-based companies from conventional manufacturing practices to disposable manufacturing systems also drives regional growth
• Asia Pacific is estimated to witness the fastest growth with emerging markets such as China and Japan at the forefront
• Collaborations between domestic and global players for expansion of biomanufacturing capabilities is driving the market in the Asia Pacific
• Key companies are focusing on new product launches to sustain their position in the market

List of Key Players in Single-use Bioprocessing Market

• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Sartorius AG
• Corning Incorporated
• Pall Corporation
• General Electric Company (GE Healthcare)
• Eppendorf AG
• Rentschler Biopharma SE
• Lonza
• Meissner Filtration Products, Inc.
• JM BioConnect
• Boehringer Ingelheim GmbH
• Infors AG
• PBS Biotech, Inc.
• Entegris, Inc.
• Danaher Corporation
• Kuhner AG
• Rentschler Biopharma SE

Access Press Release of Single-use Bioprocessing Market @ https://www.grandviewresearch.com/press-release/global-single-use-bioprocessing-market

Single-cell Analysis Market Size Worth $ 6.7 Billion By 2028: Grand View Research Inc.

San Francisco, 11 May 2021: The Report Single-cell Analysis Market Size, Share & Trends Analysis Report By Product (Consumables, Instruments), By Application (IVF, Cancer, Stem Cell), By Workflow, By End-use, By Region, And Segment Forecasts, 2021 – 2028

The global single-cell analysis market size is expected to reach USD 6.7 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.0% from 2021 to 2028. Expeditious technological advancements over the years have enabled a comprehensive analysis of transcriptome and genome in an individual cell.

Single-cell technology helps in assessing cellular heterogeneity and aids in the analysis of pathways and processes at the molecular level. This technology is evolving at a rapid pace with applications in oncology, immunology, and others. Moreover, the introduction of advanced devices that simplify transcriptomic and proteomics procedures is driving the market.

Advances in single-cell RNA sequencing (scRNAseq) allow researchers to thoroughly investigate unexplored rare cell types. The development of the microfluidics method has significantly broadened the implementation of single-cell genomic/transcriptomic analysis in the biomedical field. A substantial number of microfluidic devices have been modified for cell dissociation and tissue digestion.

The increasing number of research publications is representative of the increasing investment flow in R&D in this market. As the R&D activities are the base of innovation, these investments signify a healthy growth possibility for this market. Moreover, researchers are engaged in assessing spatial heterogeneity in gene expression profiles at a single cellular level; thus, are anticipated to boost the uptake of consumables and instruments for the analysis.

Access Research Report of Single-cell Analysis Market @ https://www.grandviewresearch.com/industry-analysis/single-cell-analysis-market

Single-cell Analysis Market Report Highlights

• The consumables segment accounted for the largest revenue share due to the high adoption and demand of products offered under this segment
• Given the wide availability of different forms of reagents, this segment is responsible for constant revenue generation
• Owing to the high-end features and the technically advanced analytical options, automated instruments contributed to maximum revenue share
• The oncology segment is majorly benefited by the advancements in single-cell analysis methods
• To avoid risks associated with cancer therapy, single-cell analysis techniques are being heavily adopted for cancer genomics
• There is increasing demand for prenatal diagnosis and non-invasive techniques for the detection of single-gene disorders associated with the fetus
• This has increased the adoption of single-cell analysis for prenatal diagnosis
• Single-cell analysis is being widely employed by various end-users, ranging from academic research institutes to biotechnology and pharmaceutical companies
• Academic and research institutes held a significant share due to wide usage across various studies
• North America dominated the 2020 global market owing to the increasing R&D of robust therapies and disease diagnosis
• Asia-Pacific is projected to witness the fastest CAGR, with India and China at the forefront
• Thermo Fisher Scientific, QIAGEN NV, Illumina Inc., Merck Millipore, BGI, Fluidigm Corporation, and Bio-Rad Laboratories are some prominent entities in this space.
• Companies have focused on the development of new innovative products to gain a competitive advantage

List of Key Players of Single-cell Analysis Market

• Thermo Fisher Scientific
• QIAGEN NV
• Illumina Inc.
• Bio-Rad Laboratories
• 10x Genomics Inc.
• Novogene Corporation
• BGI
• Fluidigm Corporation
• Merck Millipore
• Becton, Dickinson & Company

Access Press Release of Single-cell Analysis Market @ https://www.grandviewresearch.com/press-release/global-single-cell-analysis-market

Stem Cells Market Size Worth $ 18.4 Billion By 2028: Grand View Research Inc.

San Francisco, 22 March 2021: The Report Stem Cells Market Size, Share & Trends Analysis Report By Product (Mesenchymal, Adult, iPSCs), By Application, By Technology (Cell Acquisition, Cryopreservation), By Therapy, By Region, And Segment Forecasts, 2021 – 2028

The global stem cells market size is expected to reach USD 18.4 billion by 2028, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 8.8% during the forecast period. The market is driven by the rising number of stem cell banks, growing focus on increasing therapeutic potential of these, and extensive research for the development of regenerative medicines, among other factors.

Companies are receiving robust funding for the development of cellular therapies for cancer, which is anticipated to supplement the market growth. For instance, in February 2021, Notch Therapeutics, Inc. received funding of USD 85 million for developing induced pluripotent therapies for cancer. The investment will support the development of the company’s iPSC-derived T cell-based therapeutic candidates and expanding the application of their proprietary Engineered Thymic Niche (ETN) platform.

The increasing focus on regenerative medicines is further driving the market growth. The iPSCs are gaining popularity for the development of personalized cellular therapies and are creating new opportunities for regenerative medicine. For instance, in September 2020, researchers from Duke-NUS and Monash University discovered the first stem cell that can help in the treatment of placenta complications during pregnancy.

The researchers discovered a new way for creating induced trophoblast stem cells which can be used for making placenta cells. The discovery will facilitate in developing a model human placenta in vitro and enabling a pathway for future cell therapies. The administration of cell therapy demonstrated positive results in the treatment of COVID-19 patients, which is further contributing to the market growth. In January 2020, a group of researchers used stem cell treatment on patients in Beijing, China for checking its effectiveness against COVID-19.

The patients received a single infusion of mesenchymal stem cells (MSCs) which was found to be effective in developing an immune response. However, to date, there are no MSCs that are approved by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19 owing to insufficient data on their role in treating COVID-19.

Access Research Report of Stem Cells Market @ https://www.grandviewresearch.com/industry-analysis/stem-cells-market

Stem Cells Market Report Highlights

• ASCs segment accounted for the largest share of 85.7% in 2020 as it is considered as a gold standard in stem cell-based therapies. They are widely accepted owing to their consistent clinical success especially in hematopoietic transplants and there is a relatively less controversial view regarding their origin
• The iPSC segment is expected to witness a lucrative CAGR of 9.3% through 2021-2028 owing to the increasing focus of companies in using iPS for cell therapies. For instance, in July 2020, Cynata Therapeutics Limited announced positive results for the phase 1 clinical trial of CYP-001, the company’s lead induced pluripotent stem cell (iPSC)-derived Cymerus
• Regenerative medicine dominated with a market share of 89.1% in 2020 owing to increasing funding by the government for the development of regenerative medicines. For instance, in October 2020, the AusBiotech-led consortium received funding of $300,000 from MTPConnect’s Industry Growth Centre Project Fund for the development of regenerative medicines in the country
• Cell acquisition held the largest market share of 35.8% in 2020 and is expected to expand at the fastest CAGR through 2021-2028 owing to increasing research studies involving cell harvesting
• Allogenic therapy dominated with a market share of 58.2% in 2020 owing to the increasing application of allogeneic stem cell transplants for cancer treatment
• The North America market encompasses U.S. and Canada. The factors contributing to the market growth in the region include robust government funding, increasing research, and the presence of prominent players.
• Asia Pacific is expected to expand with the fastest CAGR of 9.0% through 2021 to 2028 owing to increasing expansion by key companies in this region. For instance, in April 2020, Seneca Biopharma completed its new stem cell manufacturing facility in Suzhou, China

List of Key Players of Stem Cells Market

• CELGENE CORPORATION
• STEMCELL Technologies Inc.
• Lineage Cell Therapeutics, Inc.
• Osiris Therapeutics, Inc.
• Human Longevity, Inc.
• Cynata
• Cytori Therapeutics Inc.
• Advanced Cell Technology Inc.
• Promethera Biosciences
• Mesoblast Ltd

Access Press Release of Stem Cells Market @ https://www.grandviewresearch.com/press-release/global-stem-cells-market

Upstream Bioprocessing Market Likely To Touch At USD 12.60 Billion By 2026: Grand View Research Inc.

San Francisco, 28 Dec 2020: The Report Upstream Bioprocessing Market Size, Share & Trends Analysis Report By Product (Bioreactors, Cell Culture), By Workflow, By Use Type, By Mode (In House, Outsourced), And Segment Forecasts, 2019 – 2026

The global upstream bioprocessing market size is expected to reach USD 12.60 billion by 2026, expanding at a CAGR of 12.90% during the forecast period, according to a new report by Grand View Research, Inc. Commercial success and wide acceptance of biopharmaceuticals have provided lucrative growth avenues to several in house as well as contract manufacturing biopharmaceutical companies. Furthermore, a confluence of factors, such as high demand for biosimilars and biologics, launch of improved cost-effective technologies, and growing acceptance of single-use systems have driven the revenue performance of the market.

Start-ups and new market entrants often face budget constraints while establishing new biomanufacturing plants. Thus, these entities expand their biotherapeutics portfolio by outsourcing the production process to contract services, thereby aiding in revenue growth for upstream bioprocessing services.

Continuous upstream bioprocessing has greatly benefited the bioprocessing industry. Rising implementation of methods, such as acoustic wave technology and continuous centrifugation, for clarification of bioreactor cultures tends to minimize the clarification burden. This, in turn, increases the cell-culture densities, consequently resulting in efficient upstream processes.

Ongoing advancements in cell line productivity with respect to protein expression and clone screening are expected to result in the fastest CAGR of cell culture products over the forecast period. Cell culture is considered as the most challenging and crucial step in upstream bioprocessing, and thus demands more attention with respect to technological intricacies, resulting in the largest share in the upstream bioprocessing market.

Factors such as multi-use systems incur one-time investment, are applicable for larger bioprocessing volumes and maintain the pH and oxygen accurately resulting in high usage rate of these systems. However, a paradigm shift from conventional stainless-steel bioreactors to single-use bioreactor systems has attributed to the lucrative growth of the single-use segment.

Key market players are adopting strategic initiatives, such as novel product developments, mutually beneficial partnerships, agreements, and geographical expansion to reinforce their market presence. For instance, in February 2019, Danaher Corporation signed an agreement to acquire the Biopharma business of GE Life Sciences. The acquisition broadened Danaher’s market presence with the addition of GE Biopharma’s cell culture media, single-use technologies, development instrumentation, and consumables to its existing portfolio.

Access Research Report of Upstream Bioprocessing Market @ https://www.grandviewresearch.com/industry-analysis/upstream-bioprocessing-market

Upstream Bioprocessing Market Report Highlights

• High availability of bioreactors and continuous launches of single-use bioreactors by the key market players can be attributed to the remarkable revenue share of the bioreactors segment
• Presence of well-established biopharmaceutical manufacturing firms capable of performing in-house bioproduction has led to the maximum revenue share of this segment
• Outsourced mode of upstream bioprocessing is anticipated to witness the fastest CAGR over the forecast period, owing to increase in investments and expansion of manufacturing capabilities through the integration of single-use systems in the plants by CMOs
• North America dominated the global upstream bioprocessing market as a result of the continuous innovations in biotechnology and rising preferences for biopharmaceuticals in the region. Moreover, the presence of substantial in-house biopharmaceutical manufacturers coupled with numerous investments in the U.S. biologics market has driven the growth
• Asia Pacific is poised to witness the fastest CAGR over the forecast period due to growing awareness about the rapid analytical methods that can be used for in-process control during the upstream workflows

Browse more reports of this category by Grand View Research at: https://www.grandviewresearch.com/industry/biotechnology

Grand View Research has segmented the global upstream bioprocessing market report on the basis of product, workflow, use type, mode, and region:

Upstream Bioprocessing Product Outlook (Revenue, USD Million, 2015 – 2026)

• Bioreactors/Fermenters
• Cell Culture Products
• Filters
• Bioreactors Accessories
• Bags & Containers
• Others

Upstream Bioprocessing Workflow Outlook (Revenue, USD Million, 2015 – 2026)

• Media Preparation
• Cell Culture
• Cell Separation

Upstream Bioprocessing Use Type Outlook (Revenue, USD Million, 2015 – 2026)

• Multi Use
• Single Use

Upstream Bioprocessing Mode Outlook (Revenue, USD Million, 2015 – 2026)

• In-house
• Outsourced

Upstream Bioprocessing Regional Outlook (Revenue, USD Million, 2015 – 2026)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)

Access Press Release of Upstream Bioprocessing Market @ https://www.grandviewresearch.com/press-release/global-upstream-bioprocessing-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information:www.grandviewresearch.com

T-cell Therapy Market Expected To Witness A Substantial Growth Of USD 7.51 Billion By 2026: Grand View Research Inc.

San Francisco, 28 Dec 2020: The Report T-Cell Therapy Market Size, Share & Trends Analysis Report By Modality, By Therapy (CAR T-Cell, Tumor Infiltrating Lymphocytes), By Indication (Hematologic Malignancies, Solid Tumors), And Segment Forecasts, 2019 – 2026

The global T-cell therapy market size is expected to reach USD 7.51 billion by 2026, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 15.4% from 2019 to 2026. The landmark approvals of Yescarta and Kymriah have spurred unprecedented advancements in the market. The launch of these breakthrough therapies has bolstered cash inflow for innovation, thereby driving the growth.

Expansion of the market for T-cell therapy significantly relies on shifting preference from first-line stem cell transplants and chemotherapy to third-line CAR T-cell therapy. Moreover, the ever-expanding plethora of medical conditions for which the T cell therapies is projected to bode well for the market growth. Rise in oncological disorders is projected to drive interest as well as investments in the T-cell therapy market in near future.

In contrast with the small-molecule landscape, engineered T cells market landscape is distinguished by an extensive network that encompasses several entities marked by connections academically, financially, and via technology licensing. Research bodies, and manufacturers, and regulators engage in assessing the long-term efficacy and safety of therapies to ensure safe access to patients.

By far, the antigen challenge and linked toxicity concerns have impeded the development of CAR T therapies in non-hematological malignancies. Market players are applying a data-driven approach of exploring this space to mitigate the challenge and expand the usage of T-cell therapy in indication type such as brain cancer and melanoma.

Access Research Report of T-Cell Therapy Market @ https://www.grandviewresearch.com/industry-analysis/t-cell-therapy-market

Further key findings from the report suggest:

• In the coming years, the number of hospitals implementing CAR T therapies is expected to increase, thereby driving the commercialized business model
• Research-based business modality accounted for the highest revenue generation over the past years, attributed to the presence of several research programs
• CAR-T cell therapy market share accounted for the larger revenue share of the overall T-cell therapy market in 2018 owing to the highest investment by sponsors in this therapy type
• Presence of approved products for B cell lymphoma and acute lymphocytic leukemia has resulted in the dominance of hematological malignancies in the market
• Therapy for solid tumors is expected to emerge as the lucrative source of revenue generation in the forthcoming years
• Rising research activities in CAR T-cell therapy for solid tumors, particularly, for brain & central nervous system and melanoma, is expected to benefit the key players
• North America led the global market in 2018 owing to the presence of a large number of cancer centers engaging in research activities. Moreover, U.S.-based pharma companies like Pfizer Inc. and Celgene Corporation have shifted their focus from conventional drug development to T-cell therapy space
• Asia Pacific is estimated to witness the fastest growth with China at the forefront. China has surpassed the number of CAR T clinical trials conducted in U.S. Moreover, Novartis is strategizing to secure approval for Kymriah by China regulatory authorities in the forthcoming years
• Gilead Sciences, Novartis AG, TCR2 Therapeutics Inc., Celgene Corporation, Sorrento Therapeutics, bluebird bio, and Fate Therapeutics are some key players operating in the market. They engage in mergers and acquisitions with therapy developers. Acquisition of Juno Therapeutics by Celgene in January 2018 and Kite Pharma by Gilead in August 2017 are some notable examples of acquisitions in this market

Access Press Release of T-Cell Therapy Market @ https://www.grandviewresearch.com/press-release/global-t-cell-therapy-market

Long Read Sequencing Market Size Is Poised To Reach USD 3.4 Billion By 2025: Grand View Research Inc.

San Francisco, 28 Dec 2020: The Report Long Read Sequencing Market Size, Share & Trends Analysis Report By Workflow, By Technology (SMRT Sequencing), By Product, By Application, By End Use (Academic & Clinical Research), And Segment Forecasts, 2019 – 2025

The global long read sequencing market size is expected to reach USD 3.4 billion by 2025, according to a new report by Grand View Research, Inc., registering a 23.5% CAGR over the forecast period. Rapid advancements in third-generation long-read sequence analysis techniques are expected to bring a new era of research in the field of medical and biological sciences.

In addition, advantages offered by single-molecule real-time sequencing (SMRT) and Nanopore platforms over second-generation technologies are anticipated to enhance the adoption of these protocols. For instance, long reads generated by SMRT sequencers span across possible repetitive regions and provide a comprehensive view of the whole genome. Therefore, these technologies are adopted in the identification of genetic and structural variants.

Owing to the advantages offered by long-read technology, manufacturers are increasingly enhancing their product offerings to overcome technical as well as data analysis limitations. For instance, in January 2019, Oxford Nanopore Technologies launched NanoPipe, a web server for data analysis of nanopore MinION. The software is designed such that it can be easily used by wet-lab biologists with little knowledge about bioinformatics platforms as well as experienced bioinformaticians.

Access Research Report of Long Read Sequencing Market @ https://www.grandviewresearch.com/industry-analysis/long-read-sequencing-market

Further key findings from the report suggest:

• The SMRT segment accounted for a major share by technology in 2018 and is projected to maintain its dominance throughout the forecast period. Factors such as longer reads, high accuracy, and modified base detection make SMRT a method of choice for complete genome analysis
• Nanopore technology is anticipated to witness lucrative growth owing to the portable nature of commercially available Nanopore sequencers. This property of Nanopore sequencers makes them useful in generation of immediate, real-time data during viral outbreaks in remote areas
• On the basis of product, consumables formed the largest revenue generating segment in 2018 and is estimated to remain so throughout the forecast period owing to high utilization of consumables in every step across the workflow
• By application, identification & fine mapping of structural variation occupied a major share in 2018 as long reads allow efficient distinction of haplotypes and enhance the accuracy of analysis of structural variations
• Based on workflow, the data analysis segment is expected to expand at a lucrative CAGR owing to efforts taken by several product manufacturers to enhance adoption of data analysis software
• Academic research accounted for the largest share by end use as a result of higher usage of these methodologies in research, academic workshops, and on-site bioinformatics courses offered by universities
• Asia Pacific is expected to expand at the fastest growth rate throughout the forecast period. Lucrative opportunities offered by emerging nations has attracted investments from global firms in the region
• Pacific Biosciences of California, Inc. and Oxford Nanopore Technologies Limited are some of the prominent participants operating in this market. These participants are engaged in new product development and strategic alliances to maintain market share.

Browse more reports of this category by Grand View Research at: https://www.grandviewresearch.com/industry/biotechnology

Grand View Research has segmented the global long read sequencing market on the basis of technology, product, application, work flow, end use, and region:

Long Read Sequencing Technology Outlook (Revenue, USD Million, 2014 – 2025)

• Single-Molecule Real-Time Sequencing (SMRT)
• Nanopore Sequencing

Long Read Sequencing Product Outlook (Revenue, USD Million, 2014 – 2025)

• Instruments
• Consumables
• Services

Long Read Sequencing Application Outlook (Revenue, USD Million, 2014 – 2025)

• Identification & Fine Mapping of Structural Variation
• Tandem Repeat Sequencing
• Pseudogene Discrimination 
• Resolving Allele Phasing
• Reproductive Genomics 
• Cancer 
• Viral & Microbial Sequencing
• Others

Long Read Sequencing Workflow Outlook (Revenue, USD Million, 2014 – 2025)

• Pre-Sequencing
• Sequencing
• Data Analysis

Long Read Sequencing End-use Outlook (Revenue, USD Million, 2014 – 2025)

• Academic Research
• Clinical Research
• Hospitals & Clinics
• Pharma & Biotech Entities
• Other

Long Read Sequencing Regional Outlook (Revenue, USD Million, 2014 – 2025)

• North America
• Europe
• Asia Pacific
• Latin America
• MEA

Access Press Release of Long Read Sequencing Market @ https://www.grandviewresearch.com/press-release/global-long-read-sequencing-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information:www.grandviewresearch.com